Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan

ConclusionsAnP was not cost effective compared to nP for PD-L1-positive inoperable TNBC under the Japanese condition.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research